Cost-Effectiveness of Mineralocorticoid Receptor Antagonists in Ischemic and Nonischemic Heart Failure With Reduced Ejection Fraction: Perspective From a Universal Healthcare System
Eplerenone is likely the most cost-effective MRA in Brazil considering individuals with both ischemic and nonischemic HFrEF.
Authors
- Yasmim Botelho Neiva
- Ana Cláudia Cavalcante Nogueira (ORCID: https://orcid.org/0000-0002-7869-3826)
- Marta Duran Fernandez (ORCID: https://orcid.org/0000-0002-6655-7501)
- Luís Eduardo Paim Rohde (ORCID: https://orcid.org/0000-0002-6557-393X)
- Cristiane Koeche (ORCID: https://orcid.org/0000-0003-4083-5961)
- Luiz Sérgio Fernandes de Carvalho (ORCID: https://orcid.org/0000-0001-6465-356X)
- Andrei C. Spósito (ORCID: https://orcid.org/0000-0001-7127-2052)
- Adriana J. B. A. Guimarães
- Ana Aparecida Adeodato de Souza (ORCID: https://orcid.org/0000-0002-6560-648X)
- Giselle Pinto da Silva Amaral
Institutions
- Hospital de Clínicas de Porto Alegre (BR)
Publication Details
- Journal
- Value in Health Regional Issues
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1016/j.vhri.2025.101084
- Citations
- 1
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Mylan
- Fundação de Apoio à Pesquisa do Distrito Federal